Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a ...

Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of ...

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnc ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...

Boehringer Ingelheim has acquired a licence for the development of antibody-based cancer treatments from Oxford ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cells—white blood cells ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Telix Pharmaceuticals (ASX:TLX) enters into an asset purchase agreement with antibody engineering company ImaginAb.